1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Hu, J.
Asbury, T.
Cross, T.A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biophys.J.
BIOJAU
0030
0006-3495
92
4335
4343
10.1529/biophysj.106.090183
17384070
Backbone structure of the amantadine-blocked trans-membrane domain m2 proton channel from influenza a virus.
2007
10.2210/pdb2h95/pdb
pdb_00002h95
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
1958.496
Matrix protein 2
TRANSMEMBRANE DOMAIN (RESIDUES 26-43)
4
syn
polymer
no
no
LVVAASIIGILHLILWIL
LVVAASIIGILHLILWIL
A,B,C,D
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_nmr_spectrometer
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2007-04-24
1
1
2008-05-01
1
2
2011-07-13
1
3
2022-03-09
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_spectrometer.model
RCSB
Y
RCSB
2006-06-08
REL
REL
THE PEPTIDE WAS SYNTHESIZED USING SOLID PHASE PEPTIDE SYNTHESIS. THIS SEQUENCE OCCURS NATURALLY IN THE INFLUENZA A VIRUS (UDORN/72).
sample
structures with the lowest energy
72
1
solid-State NMR PISEMA
8.8
AMBIENT
308
K
REFINEMENT WAS CARRIED OUT IN VACUO ON INITIAL MONOMER COORDINATES CONSISTING OF TWO ALPHA-HELICAL FRAGMENTS (3.6 RESIDUES PER TURN) HAVING TILT AND ROTATIONAL ORIENTATIONS WITH RESPECT TO THE BILAYER DERIVED FROM PISEMA DIPOLAR WAVE ANALYSIS. ENERGY MINIMIZATION USED A GLOBAL PENALTY FUNCTION INCORPORATING ORIENTATIONAL RESTRAINTS, HYDROGEN BONDING AND THE CHARMM EMPIRICAL FUNCTION. THE ORIENTATIONAL RESTRAINTS IMPOSED ON THE STRUCTURE DURING REFINEMENT ARE 16 15N CHEMICAL SHIFTS AND 16 15N-1H DIPOLAR COUPLINGS FROM PISEMA EXPERIMENTS. A SYMMETRIC, TETRAMERIC BUNDLE MODEL OF M2-TMD WAS CONSTRUCTED BY A SERIES OF RIGID-BODY TRANSFORMATIONS OF THE REFINED M2-TMD MONOMER. THE RESULTING HOMO-TETRAMER IS THE LOWEST FREE ENERGY CONFORMER BASED ON ROTATIONAL CONFORMATIONAL SEARCH. NOTE THAT THE HIS37 AND TRP41 SIDECHAIN POSITIONS ARE CONSISTENT WITH MEASURED ORIENTATIONAL CONSTRAINTS. THE ROTAMERIC STATES OF OTHER RESIDUES ARE TAKEN FROM A BACKBONE DEPENDENT SIDECHAIN ROTAMER LIBRARY (SCRWL).
ENERGY MINIMIZATION WITH ORIENTATIONAL CONSTRAINTS
1
lowest energy
M2-TMD (~120 mg) and DMPC (~75 mg) were first co-dissolved in 10 ml TFE, followed by the removal of the solvent under vacuum. The peptide/lipid mixture was rehydrated and sonicated to make liposomes in a citrate-borate-phosphate (CBP) buffer (pH 8.8) with 1 mM EDTA and 10 mM amantadine at 310 K. The liposomes were pelleted by ultracentrifugation . Then the pellet was spread on glass slides and dehydrated in a 75% humidity chamber. The dehydrated slides were rehydrated with 1.5 microl liter CBP buffer per slide followed by being stacked into a glass tube and incubated at 316 K for 24 hours in 96% relative humidity. Finally, the glass tube was sealed at both ends with epoxy and two glasscaps.
oriented peptide/lipid bilayer of M2_TMD and DMPC
Schwieters, Kuszewski, Tjandra, Clore
refinement
XPLOR-NIH
2.9.9
400
Bruker
AVANCE
LEU
26
n
1
LEU
26
A
VAL
27
n
2
VAL
27
A
VAL
28
n
3
VAL
28
A
ALA
29
n
4
ALA
29
A
ALA
30
n
5
ALA
30
A
SER
31
n
6
SER
31
A
ILE
32
n
7
ILE
32
A
ILE
33
n
8
ILE
33
A
GLY
34
n
9
GLY
34
A
ILE
35
n
10
ILE
35
A
LEU
36
n
11
LEU
36
A
HIS
37
n
12
HIS
37
A
LEU
38
n
13
LEU
38
A
ILE
39
n
14
ILE
39
A
LEU
40
n
15
LEU
40
A
TRP
41
n
16
TRP
41
A
ILE
42
n
17
ILE
42
A
LEU
43
n
18
LEU
43
A
LEU
26
n
1
LEU
26
B
VAL
27
n
2
VAL
27
B
VAL
28
n
3
VAL
28
B
ALA
29
n
4
ALA
29
B
ALA
30
n
5
ALA
30
B
SER
31
n
6
SER
31
B
ILE
32
n
7
ILE
32
B
ILE
33
n
8
ILE
33
B
GLY
34
n
9
GLY
34
B
ILE
35
n
10
ILE
35
B
LEU
36
n
11
LEU
36
B
HIS
37
n
12
HIS
37
B
LEU
38
n
13
LEU
38
B
ILE
39
n
14
ILE
39
B
LEU
40
n
15
LEU
40
B
TRP
41
n
16
TRP
41
B
ILE
42
n
17
ILE
42
B
LEU
43
n
18
LEU
43
B
LEU
26
n
1
LEU
26
C
VAL
27
n
2
VAL
27
C
VAL
28
n
3
VAL
28
C
ALA
29
n
4
ALA
29
C
ALA
30
n
5
ALA
30
C
SER
31
n
6
SER
31
C
ILE
32
n
7
ILE
32
C
ILE
33
n
8
ILE
33
C
GLY
34
n
9
GLY
34
C
ILE
35
n
10
ILE
35
C
LEU
36
n
11
LEU
36
C
HIS
37
n
12
HIS
37
C
LEU
38
n
13
LEU
38
C
ILE
39
n
14
ILE
39
C
LEU
40
n
15
LEU
40
C
TRP
41
n
16
TRP
41
C
ILE
42
n
17
ILE
42
C
LEU
43
n
18
LEU
43
C
LEU
26
n
1
LEU
26
D
VAL
27
n
2
VAL
27
D
VAL
28
n
3
VAL
28
D
ALA
29
n
4
ALA
29
D
ALA
30
n
5
ALA
30
D
SER
31
n
6
SER
31
D
ILE
32
n
7
ILE
32
D
ILE
33
n
8
ILE
33
D
GLY
34
n
9
GLY
34
D
ILE
35
n
10
ILE
35
D
LEU
36
n
11
LEU
36
D
HIS
37
n
12
HIS
37
D
LEU
38
n
13
LEU
38
D
ILE
39
n
14
ILE
39
D
LEU
40
n
15
LEU
40
D
TRP
41
n
16
TRP
41
D
ILE
42
n
17
ILE
42
D
LEU
43
n
18
LEU
43
D
author_defined_assembly
4
tetrameric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
Structure of the Amantadine-Blocked Influenza A M2 Proton Channel Trans-membrane Domain by Solid-state NMR spectroscopy
1
N
N
1
N
N
1
N
N
1
N
N
A
LEU
26
A
LEU
1
HELX_P
A
LEU
43
A
LEU
18
1
1
18
B
LEU
26
B
LEU
1
HELX_P
B
LEU
43
B
LEU
18
1
2
18
C
LEU
26
C
LEU
1
HELX_P
C
LEU
43
C
LEU
18
1
3
18
D
LEU
26
D
LEU
1
HELX_P
D
LEU
43
D
LEU
18
1
4
18
MEMBRANE PROTEIN
ALPHA HELIX, PROTEIN-LIGAND, MEMBRANE PROTEIN
M2_IAUSS
UNP
1
26
P35938
LVVAASIIGILHLILWIL
26
43
2H95
26
43
P35938
A
1
1
18
26
43
2H95
26
43
P35938
B
1
1
18
26
43
2H95
26
43
P35938
C
1
1
18
26
43
2H95
26
43
P35938
D
1
1
18
1
P 1